Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (445)	6/26/2002 10:23:41 AM
From: Jibacoa	Read Replies (1) \| Respond to of 544

ARIA After its low in September at the 1.66 level it has shown good support at the 3.30 to 3.55 level (after closing its November up-gap.<g>) It has resistance at the 6.25 to 6.40 level, (if it can close above 4.80)but today is trading up in spite of the general market, apparently responding to the suit against LLY after ARIA received confirmation on its patent for the regulating NF-(kappa)B cell-signaling activity.<g> The patent covers some LLY's drugs like Evista and Xigris on which ARIA could get significant royalty payments. ARIA has an exclusive license from the Whitehead Institute,MIT & Harvard. That NF-(kappa)B cell-signaling activity regulating pattent could also give ARIA significant royalties from other drugs that use that same pathway. At any rate, ARIA started with a small up-gap today, in spite of the market, reversing yesterday's drop.<g> siliconinvestor.com Bernard